港股异动 | 昭衍新药(06127)涨超4% 前三季度归母净利润8070.61万元

Core Viewpoint - Zhaoyan New Drug (06127) experienced a stock price increase of over 4%, reaching HKD 21.66 with a trading volume of HKD 209 million [1] Financial Performance - For the first three quarters of 2025, the company reported operating revenue of RMB 985 million, a year-on-year decrease of 26.23% [1] - The net profit attributable to the parent company was RMB 80.71 million, compared to a loss of RMB 70.31 million in the same period last year [1] Order Status - The total new signed orders amounted to approximately RMB 1.64 billion for the first three quarters [1] - As of the end of the reporting period, the total backlog of orders stood at approximately RMB 2.5 billion [1]